Psychedelic Policy USA 2026: Mid-Year Federal and State Update
Psychedelic policy in the USA is moving faster in 2026 than at any point in recent history. A federal executive order, a wave of state-level bills,...
Ketamine vs. Esketamine (Spravato): What the Difference Actually Means
Ketamine vs. esketamine (Spravato) is one of the most common points of confusion for people exploring treatment-resistant depression options. Both work through a similar mechanism in...
How to Talk to Your Doctor About Psychedelic Therapy
Talking to your doctor about psychedelic therapy is one of the most common points where people get stuck. This guide walks you through how to frame...
5-MeO-DMT Therapy: What the Research Shows and Why Risks Are Real
5-MeO-DMT therapy is attracting serious interest from researchers, executives, and people seeking relief from depression, anxiety, and trauma. The compound is potent, fast-acting, and increasingly the...
Psilocybin for End-of-Life Anxiety: What the Research Shows
Research into psilocybin for end-of-life anxiety has produced some of the most compelling clinical data in psychedelic science. Landmark trials at Johns Hopkins and NYU found...
Ibogaine Opioid Treatment Research: What 2025-2026 Studies Found
Ibogaine opioid treatment research has moved significantly forward in 2025 and 2026, with new clinical data, a landmark $50 million Texas state investment, and a federal...
Psychedelic Therapy Washington DC, Maryland & Virginia: 2026 Guide
Last Updated: May 2026 If you’re looking for psychedelic therapy in Washington DC, Maryland, or Virginia (DMV), your clearest option right now is ketamine, which is...
Executive Burnout Psychedelic Therapy: What the Research Shows
Executive burnout psychedelic therapy is moving from the research margins into serious clinical conversation. A growing body of peer-reviewed evidence suggests that psilocybin-assisted therapy can reduce...
Psilocybin PTSD Therapy: What the 2026 Clinical Evidence Shows
Psilocybin PTSD therapy is no longer a fringe concept. A growing body of clinical research, including Phase 2 trials published in 2025, shows that a single...
What executives are actually using psychedelic therapy for (and what the data shows)
Psychedelic therapy for executives is moving beyond reputation and into clinical evidence. A growing number of C-suite leaders are using professionally supported psilocybin and ketamine experiences...
Ready to take the next step?
Start with a complimentary conversation, or take the two-minute self-evaluation to see if this is your moment.